Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2025

Conditions
Disorder of ConsciousnessHemorrhagic Stroke
Interventions
DRUG

Cerebrolysin

30 ml cerebrolysin + 70 ml normal saline, days 4-17, once/day, intravenously

DRUG

Control

100 ml normal saline, days 4-17, once/day, IV

Trial Locations (1)

Unknown

Konkuk University Medical Center Research Coordinating Center, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ever Neuro Pharma GmbH

INDUSTRY

lead

Konkuk University Medical Center

OTHER

NCT04427241 - Efficacy and Safety of Cerebrolysin on Prolonged Disorders of Consciousness | Biotech Hunter | Biotech Hunter